Developer docs
API playgroundTry for free, no card

Search company profiles

Cronos Australia

Full company profile

uuid0006xqm

Namestring
Cronos Australia
Company typeenum
Private
Founded yearint
2016
Short descriptiontext

Cronos Australia is an ASX-listed (ASX: CAU) Melbourne-based pharmaceuticals company founded in 2016 with 11-50 employees. No active product portfolio, business model details, or commercial operations are documented in available source material.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth Yarra, Australia
HQ citystring
South Yarra
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
pharmaceutical products, pharmaceutical distribution, pharmaceutical manufacturing, therapeutic products, healthcare products
Industry1 code
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceuticals
Social media profiles1 record
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cronos Australia is classified in the source data as a pharmaceuticals company. No specific product lines, therapeutic categories, formulations, or service offerings are described in the available material. The company's web presence is inactive, with cronosaustralia.com currently parked through GoDaddy.

Differentiator
Functional benefit
Problem solved
No data
Peers10 records
TypeDirect peer
Description

Pharmaxis is an ASX-listed Australian pharmaceutical company developing therapies for inflammatory and fibrotic diseases. It is a directly comparable small-cap Australian pharmaceutical peer with similar market positioning.

TypeDirect peer
Description

Mesoblast is an ASX-listed Australian cell therapy and regenerative medicine company. It is a directly comparable small-cap Australian pharma/biotech peer operating in the same regulatory and capital markets environment.

TypeDirect peer
Description

Mayne Pharma Group is an ASX-listed specialty pharmaceutical company headquartered in Australia, focused on branded and generic pharmaceuticals. It is the most directly comparable peer to Cronos Australia given its Australian domicile, ASX listing, and pharmaceutical product focus.

TypeBroad incumbent
Description

CSL Limited is Australia's largest pharmaceutical and biotechnology company, developing vaccines, plasma products, and therapeutics globally. It is a broad incumbent in the same industry and geography as Cronos Australia, providing a useful benchmark for what an Australian pharma platform can scale into.

5Botanix Pharmaceuticals
TypeDirect peer
Description

Botanix Pharmaceuticals is an ASX-listed Australian pharmaceutical company developing cannabinoid-based therapeutics. It is a directly comparable small-cap Australian pharma peer at similar scale and listing tier.

TypeDirect peer
Description

IDT Australia is an ASX-listed pharmaceutical manufacturing company also headquartered in Melbourne, providing contract pharmaceutical manufacturing and drug development services. Its Melbourne base and similar headcount make it a particularly close comparable.

TypeDirect peer
Description

Immutep is an ASX-listed Australian biopharmaceutical company developing LAG-3 immunotherapies. It is a directly comparable Australian-listed pharmaceutical company at similar scale and stage.

TypeDirect peer
Description

Clover Corporation is an ASX-listed Australian company developing and commercialising specialty oils and nutrients for pharmaceutical and nutritional applications. It is a directly comparable small-cap Australian health/pharmaceutical peer.

TypeDirect peer
Description

Starpharma Holdings is an ASX-listed Australian pharmaceutical company developing dendrimer-based products for pharmaceutical applications. It is a directly comparable small-cap Australian pharmaceutical peer.

TypeDirect peer
Description

Antisense Therapeutics is an ASX-listed Australian biopharmaceutical company focused on antisense oligonucleotide therapeutics. It is a directly comparable small-cap Australian pharmaceutical peer.

Market position
Customer concentration

Classification, Details

No data
Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cronos Australia

Pharmaceuticalscronosaustralia.com

Cronos Australia is an ASX-listed (ASX: CAU) Melbourne-based pharmaceuticals company founded in 2016 with 11-50 employees. No active product portfolio, business model details, or commercial operations are documented in available source material.

Cronos Australia firmographics

Firmographics
Name
Cronos Australia
Website
https://cronosaustralia.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
Cronos Australia is an ASX-listed (ASX: CAU) Melbourne-based pharmaceuticals company founded in 2016 with 11-50 employees. No active product portfolio, business model details, or commercial operations are documented in available source material.
Ownership category
akta.pro rank

Cronos Australia industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Pharmaceutical products
  • Pharmaceutical distribution
  • Pharmaceutical manufacturing
  • Therapeutic products
  • Healthcare products

Where Cronos Australia is headquartered

Location

Headquarters

HQ city
South Yarra
HQ country
Australia
HQ region
Oceania

Markets served

Cronos Australia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Cronos Australia product offering

Product offering

Core offering

Cronos Australia is classified in the source data as a pharmaceuticals company. No specific product lines, therapeutic categories, formulations, or service offerings are described in the available material. The company's web presence is inactive, with cronosaustralia.com currently parked through GoDaddy.

Differentiator

Problem solved

Functional benefit

Cronos Australia technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Cronos Australia competitors and assessment

Company assessment

Direct peers

  • Pharmaxis: Pharmaxis is an ASX-listed Australian pharmaceutical company developing therapies for inflammatory and fibrotic diseases. It is a directly comparable small-cap Australian pharmaceutical peer with similar market positioning.
  • Mesoblast Limited: Mesoblast is an ASX-listed Australian cell therapy and regenerative medicine company. It is a directly comparable small-cap Australian pharma/biotech peer operating in the same regulatory and capital markets environment.
  • Mayne Pharma Group: Mayne Pharma Group is an ASX-listed specialty pharmaceutical company headquartered in Australia, focused on branded and generic pharmaceuticals. It is the most directly comparable peer to Cronos Australia given its Australian domicile, ASX listing, and pharmaceutical product focus.
  • Botanix Pharmaceuticals: Botanix Pharmaceuticals is an ASX-listed Australian pharmaceutical company developing cannabinoid-based therapeutics. It is a directly comparable small-cap Australian pharma peer at similar scale and listing tier.
  • IDT Australia: IDT Australia is an ASX-listed pharmaceutical manufacturing company also headquartered in Melbourne, providing contract pharmaceutical manufacturing and drug development services. Its Melbourne base and similar headcount make it a particularly close comparable.
  • Immutep Limited: Immutep is an ASX-listed Australian biopharmaceutical company developing LAG-3 immunotherapies. It is a directly comparable Australian-listed pharmaceutical company at similar scale and stage.
  • Clover Corporation: Clover Corporation is an ASX-listed Australian company developing and commercialising specialty oils and nutrients for pharmaceutical and nutritional applications. It is a directly comparable small-cap Australian health/pharmaceutical peer.
  • Starpharma Holdings: Starpharma Holdings is an ASX-listed Australian pharmaceutical company developing dendrimer-based products for pharmaceutical applications. It is a directly comparable small-cap Australian pharmaceutical peer.
  • Antisense Therapeutics: Antisense Therapeutics is an ASX-listed Australian biopharmaceutical company focused on antisense oligonucleotide therapeutics. It is a directly comparable small-cap Australian pharmaceutical peer.

Broad incumbents

  • CSL Limited: CSL Limited is Australia's largest pharmaceutical and biotechnology company, developing vaccines, plasma products, and therapeutics globally. It is a broad incumbent in the same industry and geography as Cronos Australia, providing a useful benchmark for what an Australian pharma platform can scale into.

Market position

Customer concentration

Cronos Australia social profiles

Digital presence

Cronos Australia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cronos Australia leadership team

Management profile

Number of profiles

Cronos Australia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cronos Australia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cronos Australia

What does Cronos Australia do?

Cronos Australia is classified in the source data as a pharmaceuticals company. No specific product lines, therapeutic categories, formulations, or service offerings are described in the available material. The company's web presence is inactive, with cronosaustralia.com currently parked through GoDaddy.

When was Cronos Australia founded?

Cronos Australia was founded in 2016. It employs 101 to 250 people.

Where is Cronos Australia based?

Cronos Australia is headquartered in South Yarra, Australia, in the Oceania region.

Who are Cronos Australia's main competitors?

Direct peers on record are Pharmaxis, Mesoblast Limited, Mayne Pharma Group, Botanix Pharmaceuticals, IDT Australia, Immutep Limited, Clover Corporation, Starpharma Holdings and Antisense Therapeutics. CSL Limited is listed as a broad incumbent.

Does Cronos Australia have an API?

No public API is recorded for Cronos Australia.

What industry is Cronos Australia in?

Cronos Australia's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireCronos Group Issues Statement on Separately Announced IPO of Cronos AustraliaCronos Group announced a separately filed IPO of Cronos Australia, issuing 40 million new shares at AUD$0.50 each for AUD$20 million. The joint venture, led by Rodney Cocks and Peter Righetti, is expected to list on the Australian Securities Exchange in November 2019. Upon completion, Cronos Group will hold approximately 31% of the issued capital.NewswireCronos Australia is Granted Manufacturing LicenseCronos Australia Pty Ltd. was granted a medicinal cannabis manufacture license by the Australian Office of Drug Control, permitting production of cannabinoid-based products. The license is a key step for expanding research and product development, with Cronos Australia planning construction of a purpose-built facility in regional Victoria.PR NewswireCronos Group Inc. Announces First Quarter 2018 ResultsCronos Group Inc. reported Q1 2018 sales of $2.9 million, a 473% increase year over year from $0.5 million in Q1 2017, with cannabis oil sales representing 29% of domestic medical patient revenue. The company also achieved a major milestone in February 2018 by becoming the first licensed cannabis producer to list on a major U.S. stock exchange, trading on NASDAQ under the symbol "CRON." Cronos Group strengthened its global position through strategic joint ventures in Australia and with MedMen Enterprises, and raised $46 million in January 2018 and an additional $100 million in April 2018 through bought deal offerings.